EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Profile of Ofatumumab in the Treatment of Multiple Sclerosis: Design, Development and Place in Therapy

Zeinab Awada, Natasha Hameed, Asaff Harel

Drug Design, Development and Therapy · 2024-12 · Volume 18 · 5985-5996

DOI: 10.2147/dddt.s315174 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2024-12. Verfasst von Zeinab Awada und 2 weiteren Autor:innen. Beteiligte Einrichtung: Northwell Comprehensive Multiple Sclerosis Center, Department of Neurology, Lenox Hill Hospital/Donald and Barbara Zucker School of Medicine at Hofst…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Multiple Sclerosis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeting B cells through monoclonal antibodies against CD20 has emerged as a highly effective strategy in managing disease activity in patients with relapsing forms of multiple sclerosis. This efficacy was initially demonstrated with rituximab and further affirmed with ocrelizumab. Ofatumumab is the first fully human IgG1 monoclonal antibody (mAb) approved for the treatment of MS. It is characterized by its convenient self-administered regimen of once-monthly subcutaneous injections. Its human antibody nature contributes to a significantly lower risk of immunogenicity compared to rituximab. Clinical trials have consistently shown its effectiveness in significantly reducing annualized relapse rates, MRI-detected lesion activity, and disability progression when compared to teriflunomide, a standard therapy for MS. Additionally, ofatumumab exhibits a manageable tolerability profile, with adverse events primarily comprising infections and injection-related reactions. This review describes ofatumumab pharmacology, core clinical trial data and clinical efficacy in addition to safety issues.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedMultiple SclerosisAnimalsHumansAntibodies, MonoclonalDrug DesignDrug Development

Stichwörter der Autor:innen

anti- CD20 monoclonal antibodiesdisease modifying therapeuticsmultiple sclerosisofatumumabrelapsing remitting multiple sclerosissafety

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, Humanizedofatumumab

Autor:innen und Institutionen

  • Northwell Comprehensive Multiple Sclerosis Center, Department of Neurology, Lenox Hill Hospital/Donald and Barbara Zucker School of Medicine at Hofstra, New York, NY, USA.
  • Northwell Comprehensive Multiple Sclerosis Center, Department of Neurology, Long Island Jewish Medical Center/ North Shore University Hospital/ Donald and Barbara Zucker School of Medicine at Hofstra, New York, NY, USA.

Zitieren

APA

Awada, Z., Hameed, N., & Harel, A. (2024). Profile of Ofatumumab in the Treatment of Multiple Sclerosis: Design, Development and Place in Therapy. Drug Design, Development and Therapy, Volume 18, 5985-5996. https://doi.org/10.2147/dddt.s315174

Vancouver

Awada Z, Hameed N, Harel A. Profile of Ofatumumab in the Treatment of Multiple Sclerosis: Design, Development and Place in Therapy. Drug Design, Development and Therapy. 2024;Volume 18:5985-5996. doi:10.2147/dddt.s315174

BibTeX
@article{Awada2024,
  author = {Awada, Zeinab and Hameed, Natasha and Harel, Asaff},
  title = {Profile of Ofatumumab in the Treatment of Multiple Sclerosis: Design, Development and Place in Therapy},
  journal = {Drug Design, Development and Therapy},
  year = {2024},
  volume = {Volume 18},
  pages = {5985--5996},
  doi = {10.2147/dddt.s315174}
}
Kostenlos starten →